Join
Live feed
·
PRReleasevia Quantisnow
Curanex Pharmaceuticals Inc logo

Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CURX (Curanex Pharmaceuticals Inc) and more on Quantisnow.